英文摘要 |
The acute phase of severe coronavirus disease 2019 (COVID-19) including pneumonia and systemic inflammation lasts approximately 2 weeks. The development of systemic inflammatory cytokine storms damages multi-organ and organ systems. Patients with acute COVID-19 infection may present a wide spectrum of clinical symptoms, from asymptomatic to severe acute respiratory failure and high mortality. In addition to severe dyspnea that may need intensive care or even respirator treatment for pneumonia symptoms, severe COVID-19 patients may also develop acute sarcopenia manifested by about 5-10% body weight loss and affect the clinical outcomes. Furthermore, long-lasting inflammatory involvement and complex immunological events may exacerbate catabolism and muscle loss in those patients with long COVID-19 for months to years. Long coronavirus disease 19 (COVID-19) is a syndrome occurring within a few months after initial COVID-19. Long COVID-19 patients may present fatigue, dyspnea, joint pain, etc., as well as significantly worse physiological function and quality of life. In this article, we discuss the epidemiology, symptoms, pathophysiologic mechanisms, and clinical management of acute sarcopenia in long COVID-19 patients. We need to raise the awareness and early detection of long COVID-19 patients with sarcopenia. To improve the clinical outcomes, a multidisciplinary approach is essential to efficiently manage the clinical scenario, including adequate nutritional support, optimal physical therapy, cardio-pulmonary rehabilitation, and psychological intervention as well. |